| Literature DB >> 34551384 |
Patrick A Brown1, Bijal Shah2, Anjali Advani3, Patricia Aoun4, Michael W Boyer5, Patrick W Burke6, Daniel J DeAngelo7, Shira Dinner8, Amir T Fathi9, Jordan Gauthier10, Nitin Jain11, Suzanne Kirby12, Michaela Liedtke13, Mark Litzow14, Aaron Logan15, Selina Luger16, Lori J Maness17, Stephanie Massaro18, Ryan J Mattison19, William May20, Olalekan Oluwole21, Jae Park22, Amanda Przespolewski23, Sravanti Rangaraju24, Jeffrey E Rubnitz25, Geoffrey L Uy26, Madhuri Vusirikala27, Matthew Wieduwilt28, Beth Lynn29, Ryan A Berardi29, Deborah A Freedman-Cass29, Mallory Campbell29.
Abstract
The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.Entities:
Mesh：
Year: 2021 PMID： 34551384 DOI： 10.6004/jnccn.2021.0042
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908